Published in Curr Protoc Microbiol on February 01, 2010
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis (2012) 1.12
Substrate recognition by the multifunctional cytochrome P450 MycG in mycinamicin hydroxylation and epoxidation reactions. J Biol Chem (2012) 0.97
Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob Agents Chemother (2012) 0.88
Rapid Chagas disease drug target discovery using directed evolution in drug-sensitive yeast. ACS Chem Biol (2016) 0.88
Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1. Bioorg Med Chem Lett (2010) 0.85
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A (2003) 9.15
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem (2000) 8.76
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol Pharmacol (1967) 4.16
Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov (2006) 3.87
Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol (1995) 3.60
Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) (2004) 3.02
Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol (2007) 2.46
A beginner's guide to radiation damage. J Synchrotron Radiat (2009) 2.26
Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe (2008) 2.13
Estriol bound and ligand-free structures of sterol 14alpha-demethylase. Structure (2004) 1.98
Identification of Mycobacterial genes that alter growth and pathology in macrophages and in mice. J Infect Dis (2007) 1.60
The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae. J Biol Chem (2006) 1.59
Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol (2006) 1.40
The mouse as a useful model of tuberculosis. Tuberculosis (Edinb) (2003) 1.37
Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. J Biol Chem (2008) 1.37
Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach. J Antimicrob Chemother (2006) 1.36
Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J Biol Chem (2007) 1.33
Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis (2009) 1.29
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob Agents Chemother (2007) 1.20
Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis. J Inorg Biochem (2002) 1.15
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett (2005) 1.13
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett (2006) 1.09
The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett (2006) 1.05
EpoK, a cytochrome P450 involved in biosynthesis of the anticancer agents epothilones A and B. Substrate-mediated rescue of a P450 enzyme. Biochemistry (2004) 1.04
Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents (2006) 1.02
X-ray structure of 4,4'-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14alpha-demethylase (CYP51). J Biol Chem (2008) 0.99
Recent progress in the CYP51 research focusing on its unique evolutionary and functional characteristics as a diversozyme P450. Front Biosci (2005) 0.98
A rapid resazurin bioassay for assessing the toxicity of fungicides. Chemosphere (2009) 0.97
Mycobacterium tuberculosis Rv1395 is a class III transcriptional regulator of the AraC family involved in cytochrome P450 regulation. J Biol Chem (2003) 0.92
Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol (2007) 0.92
Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium tuberculosis CYP121 and CYP51B1. Analysis of CO complexation reactions and reversibility of the P450/P420 equilibrium. J Biol Chem (2007) 0.90
Multiwavelength anomalous diffraction as a direct phasing vehicle in macromolecular crystallography. Basic Life Sci (1989) 0.87
The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae. J Biol Chem (2006) 1.59
Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. J Biol Chem (2005) 1.52
Mycobacterium tuberculosis CYP125A1, a steroid C27 monooxygenase that detoxifies intracellularly generated cholest-4-en-3-one. Mol Microbiol (2010) 1.49
Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J Biol Chem (2007) 1.33
The cytochrome P450 complement (CYPome) of Streptomyces coelicolor A3(2). J Biol Chem (2002) 1.32
Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis (2010) 1.30
Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis (2009) 1.29
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother (2010) 1.22
Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A (2012) 1.22
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob Agents Chemother (2007) 1.20
Engineering and analysis of a self-sufficient biosynthetic cytochrome P450 PikC fused to the RhFRED reductase domain. J Am Chem Soc (2007) 1.18
A second FMN binding site in yeast NADPH-cytochrome P450 reductase suggests a mechanism of electron transfer by diflavin reductases. Structure (2006) 1.18
Biochemical and structural characterization of CYP124: a methyl-branched lipid omega-hydroxylase from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 1.13
Sterol 14alpha-demethylase activity in Streptomyces coelicolor A3(2) is associated with an unusual member of the CYP51 gene family. Biochem J (2002) 1.13
Selective oxidation of carbolide C-H bonds by an engineered macrolide P450 mono-oxygenase. Proc Natl Acad Sci U S A (2009) 1.13
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis (2012) 1.12
Tirandamycin biosynthesis is mediated by co-dependent oxidative enzymes. Nat Chem (2011) 1.06
Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. J Biol Chem (2005) 1.04
Structural control of cytochrome P450-catalyzed ω-hydroxylation. Arch Biochem Biophys (2010) 1.01
X-ray structure of 4,4'-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14alpha-demethylase (CYP51). J Biol Chem (2008) 0.99
Substrate recognition by the multifunctional cytochrome P450 MycG in mycinamicin hydroxylation and epoxidation reactions. J Biol Chem (2012) 0.97
Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target. Beilstein J Org Chem (2013) 0.95
Structure of cytochrome P450 PimD suggests epoxidation of the polyene macrolide pimaricin occurs via a hydroperoxoferric intermediate. Chem Biol (2010) 0.95
Analysis of transient and catalytic desosamine-binding pockets in cytochrome P-450 PikC from Streptomyces venezuelae. J Biol Chem (2009) 0.93
N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets. J Am Chem Soc (2013) 0.92
Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents. J Med Chem (2013) 0.89
4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. J Med Chem (2014) 0.88
Identification of amino acids in rat pregnane X receptor that determine species-specific activation. Mol Pharmacol (2004) 0.87
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. Chem Rev (2014) 0.86
Directing group-controlled regioselectivity in an enzymatic C-H bond oxygenation. J Am Chem Soc (2014) 0.85
Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1. Bioorg Med Chem Lett (2010) 0.85
A highly conserved mycobacterial cholesterol catabolic pathway. Environ Microbiol (2013) 0.85
New reactions and products resulting from alternative interactions between the P450 enzyme and redox partners. J Am Chem Soc (2014) 0.84
Old fold in a new X-ray diffraction dataset? Low-resolution molecular replacement using representative structural templates can provide phase information. Proteins (2006) 0.82
A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis. Methods Mol Biol (2015) 0.81
Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis. J Med Chem (2014) 0.80
Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives. Chembiochem (2014) 0.79
FMN binding site of yeast NADPH-cytochrome P450 reductase exposed at the surface is highly specific. ACS Chem Biol (2010) 0.77
Ligand-assisted inhibition in cytochrome P450 158A2 from Streptomyces coelicolor A3(2). Biochemistry (2006) 0.77
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. J Med Chem (2016) 0.76
Correction: The Schistosoma mansoni Cytochrome P450 (CYP3050A1) Is Essential for Worm Survival and Egg Development. PLoS Negl Trop Dis (2016) 0.76
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. J Med Chem (2014) 0.75